Syndax Pharmaceuticals Inc (SNDX) stock
SNDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$8.56−0.64 (-6.96%)
Close on Nov 18, 2026Market cap $764.38MP/E –Yield –
Syndax Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Syndax Pharmaceuticals's revenue for the twelve months ending Sep 30, 2026 was $289.68M, up 159.7% year over year. For fiscal 2025 it was $172.35M, up 627.8% from the year before. Over ten years it grew 75.4% a year on average. The highest annual figure on record is $172.35M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $172.35M | +627.8% |
| FY2024 | Dec 31, 2024 | $23.68M | – |
| FY2023 | Dec 31, 2023 | $0 | – |
| FY2022 | Dec 31, 2022 | $0 | -100.0% |
| FY2021 | Dec 31, 2021 | $139.71M | +9109.6% |
| FY2020 | Dec 31, 2020 | $1.52M | 0.0% |
| FY2019 | Dec 31, 2019 | $1.52M | 0.0% |
| FY2018 | Dec 31, 2018 | $1.52M | -28.0% |
| FY2017 | Dec 31, 2017 | $2.11M | +72.8% |
| FY2016 | Dec 31, 2016 | $1.22M | +94.6% |
| FY2015 | Dec 31, 2015 | $627.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $83.30M | +81.6% |
| Q2 FY2026 | Jun 30, 2026 | $72.79M | +91.8% |
| Q1 FY2026 | Mar 31, 2026 | $64.86M | +223.6% |
| Q4 FY2025 | Dec 31, 2025 | $68.73M | +794.9% |
| Q3 FY2025 | Sep 30, 2025 | $45.87M | +267.0% |
| Q2 FY2025 | Jun 30, 2025 | $37.96M | +984.5% |
| Q1 FY2025 | Mar 31, 2025 | $20.04M | – |
| Q4 FY2024 | Dec 31, 2024 | $7.68M | – |
| Q3 FY2024 | Sep 30, 2024 | $12.50M | – |
| Q2 FY2024 | Jun 30, 2024 | $3.50M | – |
| Q1 FY2024 | Mar 31, 2024 | $0 | -100.0% |
| Q4 FY2023 | Dec 31, 2023 | $0 | -100.0% |
| Q3 FY2023 | Sep 30, 2023 | $0 | -100.0% |
| Q2 FY2023 | Jun 30, 2023 | $0 | -100.0% |
| Q4 FY2021 | Dec 31, 2021 | $126.58M | +33209.5% |
| Q3 FY2021 | Sep 30, 2021 | $12.38M | +3165.2% |
| Q2 FY2021 | Jun 30, 2021 | $379.00K | 0.0% |
| Q1 FY2021 | Mar 31, 2021 | $379.00K | 0.0% |
| Q4 FY2020 | Dec 31, 2020 | $380.00K | 0.0% |
| Q3 FY2020 | Sep 30, 2020 | $379.00K | 0.0% |
| Q2 FY2020 | Jun 30, 2020 | $379.00K | 0.0% |
| Q1 FY2020 | Mar 31, 2020 | $379.00K | 0.0% |
| Q4 FY2019 | Dec 31, 2019 | $380.00K | 0.0% |
| Q3 FY2019 | Sep 30, 2019 | $379.00K | 0.0% |
| Q2 FY2019 | Jun 30, 2019 | $379.00K | 0.0% |
| Q1 FY2019 | Mar 31, 2019 | $379.00K | 0.0% |
| Q4 FY2018 | Dec 31, 2018 | $380.00K | -68.1% |
| Q3 FY2018 | Sep 30, 2018 | $379.00K | +24.3% |
| Q2 FY2018 | Jun 30, 2018 | $379.00K | +24.3% |
| Q1 FY2018 | Mar 31, 2018 | $379.00K | +24.3% |
| Q4 FY2017 | Dec 31, 2017 | $1.19M | +291.1% |
| Q3 FY2017 | Sep 30, 2017 | $305.00K | – |
| Q2 FY2017 | Jun 30, 2017 | $305.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $305.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $305.00K | – |
See a number that looks wrong?